# A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

> **NCT06907043** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eikon Therapeutics** · enrollment: 130 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** EIK1004-001 (IMP1707-001)

## Key facts

- **NCT ID:** NCT06907043
- **Lead sponsor:** Eikon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907043, "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06907043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*